WealthShield Partners LLC Has $792,000 Holdings in Johnson & Johnson (NYSE:JNJ)

WealthShield Partners LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 14.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,475 shares of the company’s stock after selling 939 shares during the quarter. WealthShield Partners LLC’s holdings in Johnson & Johnson were worth $792,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Knuff & Co LLC boosted its stake in shares of Johnson & Johnson by 0.7% in the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after buying an additional 64 shares during the period. Vertex Planning Partners LLC raised its holdings in Johnson & Johnson by 1.3% in the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after acquiring an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management lifted its position in shares of Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock valued at $301,000 after acquiring an additional 66 shares during the period. Corepath Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 3.7% during the 4th quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock worth $287,000 after purchasing an additional 70 shares in the last quarter. Finally, Lifestyle Asset Management Inc. increased its position in shares of Johnson & Johnson by 4.7% in the fourth quarter. Lifestyle Asset Management Inc. now owns 1,560 shares of the company’s stock worth $226,000 after purchasing an additional 70 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of analyst reports. Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Wells Fargo & Company dropped their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Trading Down 2.0 %

JNJ opened at $162.75 on Thursday. The company’s 50 day moving average price is $150.08 and its two-hundred day moving average price is $155.97. The firm has a market capitalization of $391.83 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the company earned $2.29 EPS. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.05%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.